Sang Wan Kim

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, Egbert F. Smit, David Planchard et al. · Annals of Oncology · 2015 · 360 citations · Full text

Medicine, Oncology, Pharmacology +14

Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts

Sang Wan Kim, Paola Divieti Pajevic, Martin K. Selig et al. · Journal of Bone and Mineral Research · 2012 · 262 citations

Medicine, Endocrinology, Molecular Biology +15

Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer

Chang Gok Woo, Seyoung Seo, Sang Wan Kim et al. · Annals of Oncology · 2016 · 215 citations · Full text

Medicine, Cancer Biology, Oncology +16

Activation of Peroxisome Proliferator-activated Receptor-γ Inhibits the Runx2-mediated Transcription of Osteocalcin in Osteoblasts

Min Jae Jeon, Jeong Ah Kim, Sung Hee Kwon et al. · Journal of Biological Chemistry · 2003 · 214 citations · Full text

Medicine, Cell Biology, Molecular Biology +14

Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells

Sang Wan Kim, Sang Wan Kim, Sun Ju Her et al. · Bone · 2005 · 205 citations

Medicine, Cell Biology, Endocrinology +12